Townsquare Capital LLC Has $1.26 Million Position in Amgen Inc. $AMGN

Townsquare Capital LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 48.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,843 shares of the medical research company’s stock after selling 3,602 shares during the period. Townsquare Capital LLC’s holdings in Amgen were worth $1,258,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Robeco Institutional Asset Management B.V. boosted its stake in Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC bought a new position in Amgen in the fourth quarter valued at approximately $1,669,000. Adell Harriman & Carpenter Inc. boosted its stake in Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock valued at $7,204,000 after acquiring an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in Amgen in the fourth quarter valued at approximately $22,441,000. Finally, Sigma Planning Corp boosted its position in shares of Amgen by 24.0% during the fourth quarter. Sigma Planning Corp now owns 17,992 shares of the medical research company’s stock worth $5,889,000 after purchasing an additional 3,488 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent analyst reports. UBS Group lifted their price target on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Jefferies Financial Group initiated coverage on shares of Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target on the stock. Wall Street Zen cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Rothschild & Co Redburn lifted their price target on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Finally, Royal Bank Of Canada lifted their price target on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $354.12.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s obesity drug MariTide is drawing attention as a potential growth driver, with analysts noting that its less frequent dosing could help the company compete in the fast-growing GLP-1/obesity market. Article Title
• Positive Sentiment: Amgen’s broader growth pipeline is being viewed as a potential offset to patent-related pressure, with some commentary suggesting 2026 could be a “springboard” year if newer drugs gain traction. Article Title
• Neutral Sentiment: Goldman Sachs trimmed its price target on Amgen but kept a Buy rating, signaling some caution on valuation while still seeing upside potential. Article Title
• Neutral Sentiment: Recent market commentary noted that Amgen has underperformed some peers and posted a bigger drop than the broader market, reflecting short-term profit-taking and weaker relative momentum. Article Title
• Negative Sentiment: Market coverage also flagged that Amgen fell more than the market in the latest session, reinforcing concern that investors may be locking in gains after the stock’s strong multi-year run. Article Title

Amgen Trading Down 2.0%

AMGN opened at $337.73 on Thursday. The stock has a market capitalization of $182.28 billion, a P/E ratio of 23.50, a P/E/G ratio of 3.46 and a beta of 0.42. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The firm’s fifty day simple moving average is $340.89 and its 200 day simple moving average is $345.53. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.